Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer

Ingmar F. Rompen,Joseph R. Habib,Christopher L. Wolfgang,Ammar A. Javed

DOI: https://doi.org/10.3390/cancers16030489

2024-01-24

Cancers

Abstract:Pancreatic ductal adenocarcinoma (PDAC) remains associated with poor outcomes with a 5-year survival of 12% across all stages of the disease. These poor outcomes are driven by a delay in diagnosis and an early propensity for systemic dissemination of the disease. Recently, aggressive surgical approaches involving complex vascular resections and reconstructions have become more common, thus allowing more locally advanced tumors to be resected. Unfortunately, however, even after the completion of surgery and systemic therapy, approximately 40% of patients experience early recurrence of disease. To determine resectability, many institutions utilize anatomical staging systems based on the presence and extent of vascular involvement of major abdominal vessels around the pancreas. However, these classification systems are based on anatomical considerations only and do not factor in the burden of systemic disease. By integrating the biological criteria, we possibly could avoid futile resections often associated with significant morbidity. Especially patients with anatomically resectable disease who have a heavy burden of radiologically undetected systemic disease most likely do not derive a survival benefit from resection. On the contrary, we could offer complex resections to those who have locally advanced or oligometastatic disease but have favorable systemic biology and are most likely to benefit from resection. This review summarizes the current literature on defining anatomical and biological resectability in patients with pancreatic cancer.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the anatomical and biological considerations for determining the surgical feasibility of pancreatic cancer. Specifically, the paper focuses on how to more accurately judge whether a patient is suitable for surgical treatment by integrating the anatomical relationship between the tumor and important blood vessels and the biological characteristics of the tumor (such as invasiveness). Traditionally, the surgical feasibility of pancreatic cancer is mainly based on anatomical criteria, such as tumor size and its relationship with important blood vessels such as the hepatic portal vein and the superior mesenteric artery. However, these criteria do not take into account the systemic disease burden of the tumor, resulting in early recurrence in some patients after surgery.

The paper points out that for patients who are anatomically resectable but have undetected systemic disease burden, surgery may not bring survival benefits. Conversely, for patients with locally advanced or oligometastatic lesions but with favorable systemic biological characteristics, complex surgical resection may be beneficial. Therefore, the paper emphasizes the importance of combining biological assessment to avoid unnecessary surgeries and ensure that the surgery can bring the greatest survival benefits to patients.

In summary, the main purpose of this paper is to explore how to more accurately assess the surgical feasibility of pancreatic cancer patients by integrating anatomical and biological factors, thereby optimizing treatment strategies and improving patient survival rates.